Form D · Biotechnology

ADARx Pharmaceuticals, Inc.

San Diego, CA · CIK 0001802369

Offering snapshot reported Aug 10, 2023 · SEC filing

Reported sold
$200M
Offering amount: $200M
Investors reported
28
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 2, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 10, 2023Initial$200,000,012No comparison28SEC filing
Jan 26, 2023Initial$45,999,999No comparison10SEC filing
Aug 17, 2021Initial$74,999,996No comparison6SEC filing
May 24, 2021Initial$15,499,998No comparison3SEC filing
Nov 17, 2020Initial$6,000,000No comparison3SEC filing
Aug 7, 2020Initial$5,000,000No comparison3SEC filing
Feb 6, 2020Initial$5,000,000No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-489353

Source: Form D, filed Aug 10, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Erez Chimovits Director
Simeon George Director
Carl Gordon Director
Sheila Gujrathi Director
Lorence Kim Director
Zhen Li Director, Executive, Promoter
Judith Li Director
Hongbo Lu Director
Yuan Sun Director
Yuan (Eliza) Sun Director
Ricky Sun Director
Chen Yu Director
Xiong Zhang Director
Rui Zhu Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5871 Oberlin Drive, Suite 200
San Diego, CA, 92121